Learn the GLP-1 weight loss category.

Most patients describe the first 8-16 weeks as 'food noise turned off, weight falling effortlessly'. Then something shifts. The honeymoon is real, the cliff after it is also real and understanding both is the difference between long-term success and abandonment.

Two manufacturer assistance programs supply Ozempic, Wegovy, Mounjaro and Zepbound at no cost to income-qualifying uninsured patients, and a copay card takes insured patients to $25 a month. Below those sit 340B clinic pricing, 503B compounding and two searchable databases. Each entry lists what it asks for.

MHRA and EMA reviewed the 2023-2024 reports of suicidal ideation on GLP-1. The verdict was no causal link. Here is the data, the limits, and what patients on SSRIs should know.

Both drugs work. The 5-year cash bill varies by a factor of 10 depending on insurance, HSA use and which manufacturer direct program you route through. Here is the math, with worked examples for cash-pay, insurance-approved and HSA scenarios.

Patients with obstructive sleep apnea hear about GLP-1s and assume Wegovy qualifies. It does not. The OSA indication belongs to Zepbound, not Wegovy, and that single regulatory fact reshapes coverage, prior authorization and cash-pay strategy.

Tirzepatide produced histologic resolution of MASH in roughly 62 percent of patients in SYNERGY-NASH at 52 weeks. That is the largest effect any drug has shown in the disease. Zepbound still has no MASH indication. Wegovy got one on its June 2026 label.

The SUMMIT trial showed tirzepatide reduced the composite of CV death and worsening heart-failure events by 38 percent in patients with HFpEF and obesity. The Zepbound label never followed. Prescribing it for heart failure is off-label, and coverage still has to be built on obesity or sleep apnea.

Cancel the old program too early and you lose the prescription. Too late and you pay double. Here is the exact sequencing for a clean switch.

We read the four current FDA labels on Monday, August 17, 2026, and multiplied out what maintenance costs at every program on our chart with a verified price. Wegovy's June 2026 label added a 7.2 mg ceiling above the 2.4 mg maintenance dose. Three withdrawal clinical trials measured what happened after people stopped.

Nine of the telehealth programs we track bundle compounded medication into the monthly fee. Here is the verified list with pricing, the nuances that matter, and how to compare total cost fairly against programs that charge separately.

Most GLP-1 telehealth programs let you cancel online with no fee. A handful do not, and the ones that bury a 12-month lock or a phone-only cancellation are the ones that cost people money. Here is the verified breakdown for all programs we track.

Tirzepatide costs more than compounded semaglutide at most programs, but not all. Mochi Health charges a flat $178 a month for its compounded GLP-1 program regardless of molecule. Below that, the numbers come with catches: minimum commitments, pricing-at-signup opacity, or 12-month lock-ins. Plus the regulatory risk specific to tirzepatide that the semaglutide list does not carry.